UNIVERSAL BIOSENSORS INC. — M&A Activity 2016

Dec 18, 2016

Universal Biosensors Inc ARBN 121 559 993 1 Corporate Avenue Rowville VIC 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email info@universalbiosensors.com www.universalbiosensors.com

==> picture [129 x 88] intentionally omitted <==

19 December 2016

Universal Biosensors acquires the Hemostasis Reference Laboratory business of LifeLabs to meet increased production demands of Siemen’s Xprecia Stride[TM] test strips

Universal Biosensors, Inc (ASX: UBI ) has today announced that a wholly-owned Canadian operating subsidiary has signed an agreement with LifeLabs LP ( LifeLabs ) to acquire the assets of LifeLabs’ Hemostasis Reference Laboratory business ( HRL ) in preparation for future increased production requirements of Siemens’ Xprecia Stride[TM] test strips.

The HRL business has provided high-quality coagulation testing and calibration services to international customers for more than 20 years, including 5 years of services for UBI. HRL has one of the most diverse offerings of specialised coagulation services in the world. Its laboratory currently has 16 different coagulation analyzers available, representing every major manufacturer for a very diverse list of testing options. The HRL business is based out of leased offices in Canada and has approximately 14 employees who will transfer to Universal Biosensors’ wholly-owned Canadian subsidiary.

Strips produced by UBI are required to be calibrated so that all PT/INR products agree with an international standard. The acquisition of HRL gives UBI more control, certainty and reduces risks in meeting expanded production demand.

The acquisition has been funded with existing cash reserves and is not expected to have a material impact on the consolidated results of Universal Biosensors. The terms of the acquisition are confidential.

Executive Chairman Andy Denver says: “The production demand for Siemen’s Xprecia Stride[TM] test strips has increased significantly. The acquisition of HRL’s assets is a strategic move to ensure that we have better control of our entire manufacturing process and to streamline UBI’s production of test strips with more certainty to continue to meet stringent international standard.”

Ends

Enquiries: Mr. Salesh Balak Mr. Andrew Denver +61 3 9213 9000

About Universal Biosensors

For additional information regarding Universal Biosensors, refer to: http://www.universalbiosensors.com/.

Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture, and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

Universal Biosensors Inc ARBN 121 559 993 1 Corporate Avenue Rowville VIC 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email info@universalbiosensors.com www.universalbiosensors.com

==> picture [129 x 88] intentionally omitted <==

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement because of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.